An Open-label Exploratory Study With Memantine: Correlation Between Proton Magnetic Resonance Spectroscopy, Cerebrospinal Fluid Biomarkers, and Cognition in Patients With Mild to Moderate Alzheimer's Disease.

Trial Profile

An Open-label Exploratory Study With Memantine: Correlation Between Proton Magnetic Resonance Spectroscopy, Cerebrospinal Fluid Biomarkers, and Cognition in Patients With Mild to Moderate Alzheimer's Disease.

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Mar 2016

At a glance

  • Drugs Memantine (Primary)
  • Indications Alzheimer's disease
  • Focus Pharmacodynamics
  • Most Recent Events

    • 01 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 24 May 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 22 Jul 2010 Planned end date changed from 1 Dec 2010 to 1 Jun 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top